Otonomy to Report Third Quarter 2018 Financial Results and Provide Corporate Update
October 29, 2018 07:30 ET
|
Otonomy, Inc.
Webcast and Conference Call to be Held at 4:30 p.m. EST on November 5, 2018 SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the...
Otonomy to Report First Quarter 2018 Financial Results and Provide Corporate Update
May 02, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
January 05, 2017 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at the J.P. Morgan Healthcare Conference
January 03, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO® in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes
October 04, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at Baird Global Healthcare Conference
September 01, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO™ in Patients with Acute Otitis Externa
June 09, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO™
May 20, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 20, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces OTIPRIO™ Data Presentation and Symposium at Combined Otolaryngology Spring Meetings
May 16, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
March 07, 2016 16:14 ET
|
Otonomy, Inc.
SAN DIEGO, March 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...